213 related articles for article (PubMed ID: 34244299)
21. Tracking dendritic cell migration into lymph nodes by using a novel PET probe
Lee SB; Lee HW; Lee H; Jeon YH; Lee SW; Ahn BC; Lee J; Jeong SY
EJNMMI Res; 2017 Dec; 7(1):32. PubMed ID: 28378292
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
23. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model.
Singh AP; Zheng X; Lin-Schmidt X; Chen W; Carpenter TJ; Zong A; Wang W; Heald DL
MAbs; 2020; 12(1):1688616. PubMed ID: 31852337
[TBL] [Abstract][Full Text] [Related]
24. Trafficking macrophage migration using reporter gene imaging with human sodium iodide symporter in animal models of inflammation.
Seo JH; Jeon YH; Lee YJ; Yoon GS; Won DI; Ha JH; Jeong SY; Lee SW; Ahn BC; Lee J
J Nucl Med; 2010 Oct; 51(10):1637-43. PubMed ID: 20847173
[TBL] [Abstract][Full Text] [Related]
25. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy.
Stock S; Schmitt M; Sellner L
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835562
[TBL] [Abstract][Full Text] [Related]
26. Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.
Yan L; Qu S; Shang J; Shi X; Kang L; Xu N; Zhu M; Zhou J; Jin S; Yao W; Yao Y; Chen G; Chang H; Zhu X; Yu L; Wu D; Fu C
Cancer Med; 2021 Jan; 10(2):563-574. PubMed ID: 33356013
[TBL] [Abstract][Full Text] [Related]
27. Quantitative Systems Pharmacology Model of Chimeric Antigen Receptor T-Cell Therapy.
Hardiansyah D; Ng CM
Clin Transl Sci; 2019 Jul; 12(4):343-349. PubMed ID: 30990958
[TBL] [Abstract][Full Text] [Related]
28. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
29. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
Schmohl KA; Gupta A; Grünwald GK; Trajkovic-Arsic M; Klutz K; Braren R; Schwaiger M; Nelson PJ; Ogris M; Wagner E; Siveke JT; Spitzweg C
Oncotarget; 2017 May; 8(20):33393-33404. PubMed ID: 28380420
[TBL] [Abstract][Full Text] [Related]
30. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of [(18)F]tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter.
Jauregui-Osoro M; Sunassee K; Weeks AJ; Berry DJ; Paul RL; Cleij M; Banga JP; O'Doherty MJ; Marsden PK; Clarke SE; Ballinger JR; Szanda I; Cheng SY; Blower PJ
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2108-16. PubMed ID: 20577737
[TBL] [Abstract][Full Text] [Related]
32.
Sakemura R; Can I; Siegler EL; Kenderian SS
Mol Ther Oncolytics; 2021 Mar; 20():625-633. PubMed ID: 33816781
[TBL] [Abstract][Full Text] [Related]
33. Uptake of [¹⁸F]tetrafluoroborate in MCF-7 Breast Cancer Cells is Induced after Stimulation of the Sodium Iodide Symporter.
Lehmacher M; Stolzenburg A; Samnick S
Curr Cancer Drug Targets; 2020; 20(2):146-155. PubMed ID: 32056515
[TBL] [Abstract][Full Text] [Related]
34. Ectopic expression of the sodium-iodide symporter enables imaging of transplanted cardiac stem cells in vivo by single-photon emission computed tomography or positron emission tomography.
Terrovitis J; Kwok KF; Lautamäki R; Engles JM; Barth AS; Kizana E; Miake J; Leppo MK; Fox J; Seidel J; Pomper M; Wahl RL; Tsui B; Bengel F; Marbán E; Abraham MR
J Am Coll Cardiol; 2008 Nov; 52(20):1652-60. PubMed ID: 18992656
[TBL] [Abstract][Full Text] [Related]
35. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies.
Penheiter AR; Russell SJ; Carlson SK
Curr Gene Ther; 2012 Feb; 12(1):33-47. PubMed ID: 22263922
[TBL] [Abstract][Full Text] [Related]
36. The sodium iodide symporter (NIS) as theranostic gene: its emerging role in new imaging modalities and non-viral gene therapy.
Kitzberger C; Spellerberg R; Morath V; Schwenk N; Schmohl KA; Schug C; Urnauer S; Tutter M; Eiber M; Schilling F; Weber WA; Ziegler S; Bartenstein P; Wagner E; Nelson PJ; Spitzweg C
EJNMMI Res; 2022 May; 12(1):25. PubMed ID: 35503582
[TBL] [Abstract][Full Text] [Related]
37. PET Reporter Gene Imaging and Ganciclovir-Mediated Ablation of Chimeric Antigen Receptor T Cells in Solid Tumors.
Murty S; Labanieh L; Murty T; Gowrishankar G; Haywood T; Alam IS; Beinat C; Robinson E; Aalipour A; Klysz DD; Cochran JR; Majzner RG; Mackall CL; Gambhir SS
Cancer Res; 2020 Nov; 80(21):4731-4740. PubMed ID: 32958548
[TBL] [Abstract][Full Text] [Related]
38. Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography.
Shalaby N; Xia Y; Kelly JJ; Sanchez-Pupo R; Martinez F; Fox MS; Thiessen JD; Hicks JW; Scholl TJ; Ronald JA
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38722382
[TBL] [Abstract][Full Text] [Related]
39. A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells.
Aoyama S; Yasuda S; Li H; Watanabe D; Umezawa Y; Okada K; Nogami A; Miura O; Kawamata N
Int J Mol Med; 2022 Apr; 49(4):. PubMed ID: 35119085
[TBL] [Abstract][Full Text] [Related]
40. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
Ruella M; Barrett DM; Kenderian SS; Shestova O; Hofmann TJ; Perazzelli J; Klichinsky M; Aikawa V; Nazimuddin F; Kozlowski M; Scholler J; Lacey SF; Melenhorst JJ; Morrissette JJ; Christian DA; Hunter CA; Kalos M; Porter DL; June CH; Grupp SA; Gill S
J Clin Invest; 2016 Oct; 126(10):3814-3826. PubMed ID: 27571406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
